When was Photocure founded?

Photocure was founded in 1993 and raised its 1st funding round 27 years after it was founded.

Where is Photocure located?

Photocure is headquartered in Oslo, Norway.

How many employees does Photocure have?

As of Sep 30, 2026, the latest employee count at Photocure is 138.

Is Photocure a funded company?

Photocure is a funded company, having raised a total of $***** in its 1st and only funding round, a Post IPO round on Apr 27, 2020.

When was the latest funding round of Photocure?

Photocure's latest funding was a $***** Post IPO round on Apr 27, 2020, with participation from 0 investor.

Where does Photocure rank among its competitors?

Photocure ranks 745th amongst 3317 active competitors, of which 1117 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Photocure?

Photocure's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Photocure - 2026 Company Profile, Funding & Competitors

Photocure is a public company based in Oslo (Norway), founded in 1993. It operates as a Provider of photodynamic therapy solutions for bladder, colorectal, and cervical cancer. Photocure has raised an undisclosed amount in funding. The company has 3317 active competitors, including 1117 funded and 780 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.

Company Details

Provider of photodynamic therapy solutions for bladder, colorectal, and cervical cancer. Based on photocure technology the company has developed and commercialized Hexvix and Cysview for use in bladder cancer.

Website: photocure.com
Social
Email ID: *****@photocure.no

Key Metrics

Founded Year

1993

Location

Oslo, Norway

Stage

Public

Latest Funding Round

Post IPO, Apr 27, 2020, $*****

Investors

Radforsk

Ranked

745^th among 3317 active competitors

Employee Count

138 as on Sep 30, 2026

Investment & Acquisitions

Vesica Health

Similar Companies

Jazz Pharmaceuticals & 2988 more

Exit Details

Public

View Photocure's full profile

Photocure is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Reports
Photocure Asa CIN: 967598593 , Norway, Active	Dec 31, 1992	-	-
PHOTOCURE INC. CIN: 273217026 , United States, Active	Dec 31, 1999	-	44 (As on Dec 31, 2022)	-

Photocure got listed on Apr 03, 2008.

Click here to take a look at Photocure's IPO in detail

Photocure has raised funding over 1 round. Photocure has 1 institutional investor.

Here is the list of recent funding rounds of Photocure:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 27, 2020	5536665	Post IPO	6328819	1879434	6811841	4619646

Access funding benchmarks and valuations. Sign up today!

View details of Photocure's funding rounds and investors

Photocure's employee count trend

Photocure has 138 employees as of Sep 26. Here is Photocure's employee count trend over the years:

Uncover Photocure's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Photocure include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Photocure, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, Leaps by Bayer & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
9th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, True North & 23 others	72/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
745th	Photocure 1993, Oslo (Norway), Public	Provider of photodynamic therapy solutions for bladder, colorectal, and cervical cancer	-	Radforsk	49/100